Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Assets (2016 - 2025)

Seres Therapeutics' Non-Current Assets history spans 11 years, with the latest figure at $91.9 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 13.11% year-over-year to $91.9 million; the TTM value through Sep 2025 reached $386.3 million, down 39.41%, while the annual FY2024 figure was $101.1 million, 44.79% down from the prior year.
  • Non-Current Assets for Q3 2025 was $91.9 million at Seres Therapeutics, down from $95.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $183.2 million in Q4 2023 and bottomed at $37.5 million in Q3 2021.
  • The 5-year median for Non-Current Assets is $98.1 million (2025), against an average of $105.9 million.
  • The largest annual shift saw Non-Current Assets surged 200.64% in 2022 before it crashed 44.85% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $51.2 million in 2021, then soared by 200.64% to $154.0 million in 2022, then rose by 18.94% to $183.2 million in 2023, then tumbled by 44.79% to $101.1 million in 2024, then dropped by 9.09% to $91.9 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Non-Current Assets are $91.9 million (Q3 2025), $95.1 million (Q2 2025), and $98.1 million (Q1 2025).